Sign in Subscribe
Biotechnology industries

Aastrom Biosciences Added to Russell 3000 Index

Strategic Insights

— 1 min read

Aastrom Biosciences, Inc. (ASTM), a leader in the development of patient-specific products for tissue repair and regeneration, has announced its inclusion in the Russell 3000 Index. This significant milestone for the company marks its recognition as one of the 3,000 largest U.S. companies based on total market capitalization. As a result of its membership in the Russell 3000 Index, Aastrom Biosciences will automatically be included in other Russell indexes, making it more accessible to investment managers and institutional investors. This development is expected to boost the company's visibility and credibility in the market.

Key Takeaways:

  • Aastrom Biosciences, Inc. (ASTM) was added to the Russell 3000 Index effective at the close of market on Friday, June 24, 2005.
  • The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies based on total market capitalization.
  • Membership in the Russell 3000 Index remains in place for 1 year.
  • Russell determines membership for its equity indexes primarily by objective market capitalization rankings.
  • Aastrom Biosciences is developing patient-specific products for tissue repair and regeneration using its proprietary adult stem cell technology.
  • The company's Tissue Repair Cells (TRCs) are a mix of bone marrow-derived adult stem and progenitor cells used in products for severe bone fractures, ischemic vascular disease, jaw reconstruction, and spine fusion.
  • Phase I/II level clinical trials are active in the U.S. and EU for some of these indications.
  • Aastrom Biosciences' strategic position in the tissue regeneration sector is enabled by its proprietary Tissue Repair Cells (TRCs) and the AastromReplicell System.
  • The AastromReplicell System is an industry-unique automated cell production platform used to produce cells for clinical use.

Statistics:

  • 3,000: The number of largest U.S. companies measured by the Russell 3000 Index.
  • 1 year: The duration of membership in the Russell 3000 Index.
  • 2005: The year Aastrom Biosciences was added to the Russell 3000 Index.
  • Phase I/II: The level of clinical trials active in the U.S. and EU for some of Aastrom Biosciences' indications.
  • U.S. and EU: The geographic regions where Aastrom Biosciences' phase I/II clinical trials are active.

Sources:

  • Health & Medicine Week
  • NewsRx.com
  • Aastrom Biosciences, Inc.

Read more